[Gonadotrophin-releasing hormone agonist in the treatment of hypogonadotrophic secondary amenorrhoea].
In an attempt to induce ovulation in Clomiphene resistant secondary amenorrhoea patients, the gonadotrophin-releasing hormone agonist (Buserelin) (600-900 micrograms/day) was administered in 13 cases aged 18 to 24 years for one week from day 5 of the menstrual cycle. Serum levels of luteinizing hormone increased in all patients, and estradiol levels increased in 10 of 13 patients in response to Buserelin. However, ovulation was observed in 6 cases, and the response to Clomiphene was recovered in all of these 6 cases in their subsequent menstrual cycles. These results imply the existence of a subgroup who respond to Buserelin in Clomiphene resistant secondary amenorrhoea patients and a possible new approach for the treatment of secondary amenorrhoea.
Ishihara
O
O
Department of Obstetrics & Gynaecology, Saitama Medical Centre, Saitama Medical School, Kawagoe.
Ihno
Y
Y
Saitoh
M
M
Seki
H
H
Kinoshita
K
K
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D002064:Buserelin / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction
D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin